Bank of Montreal Can Purchases 7,677 Shares of Fortrea Holdings Inc. (NASDAQ:FTRE)

featured-image

Bank of Montreal Can raised its stake in shares of Fortrea Holdings Inc. (NASDAQ:FTRE – Free Report) by 53.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 21,983 shares of the company’s stock after purchasing an additional 7,677 shares during the period. Bank of Montreal Can’s [...]

Bank of Montreal Can raised its stake in shares of Fortrea Holdings Inc. ( NASDAQ:FTRE – Free Report ) by 53.7% in the fourth quarter, according to its most recent 13F filing with the SEC.

The fund owned 21,983 shares of the company’s stock after purchasing an additional 7,677 shares during the period. Bank of Montreal Can’s holdings in Fortrea were worth $410,000 as of its most recent SEC filing. A number of other hedge funds have also recently bought and sold shares of the company.



FMR LLC raised its stake in shares of Fortrea by 67.7% during the 4th quarter. FMR LLC now owns 8,086,806 shares of the company’s stock worth $150,819,000 after purchasing an additional 3,265,402 shares during the period.

Peregrine Capital Management LLC bought a new stake in Fortrea during the 4th quarter valued at $5,627,000. Trexquant Investment LP bought a new stake in shares of Fortrea during the fourth quarter valued at about $4,621,000. Vanguard Group Inc.

lifted its holdings in shares of Fortrea by 1.2% in the fourth quarter. Vanguard Group Inc.

now owns 9,884,256 shares of the company’s stock worth $184,341,000 after buying an additional 120,599 shares in the last quarter. Finally, Easterly Investment Partners LLC bought a new position in shares of Fortrea in the fourth quarter worth $1,902,000. Analysts Set New Price Targets Several research analysts recently issued reports on FTRE shares.

Robert W. Baird set a $12.00 target price on shares of Fortrea in a research report on Tuesday, March 4th.

Barclays reissued an “underweight” rating and set a $6.00 price objective (down from $12.00) on shares of Fortrea in a research report on Thursday, April 10th.

Mizuho decreased their target price on Fortrea from $12.00 to $10.00 and set a “neutral” rating for the company in a research report on Wednesday, April 9th.

William Blair reaffirmed a “market perform” rating on shares of Fortrea in a research report on Tuesday, March 4th. Finally, The Goldman Sachs Group cut their target price on Fortrea from $22.00 to $11.

00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Two investment analysts have rated the stock with a sell rating and ten have issued a hold rating to the company’s stock. Based on data from MarketBeat, Fortrea has an average rating of “Hold” and an average target price of $16.

70. Fortrea Trading Up 5.8 % Shares of FTRE stock opened at $5.

50 on Wednesday. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.

18 and a quick ratio of 1.18. The firm has a fifty day moving average price of $9.

38 and a 200-day moving average price of $15.51. The company has a market cap of $496.

10 million, a price-to-earnings ratio of -1.61, a PEG ratio of 1.78 and a beta of 2.

10. Fortrea Holdings Inc. has a 1 year low of $4.

77 and a 1 year high of $38.04. Fortrea ( NASDAQ:FTRE – Get Free Report ) last released its earnings results on Monday, March 3rd.

The company reported $0.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.36 by ($0.

18). The business had revenue of $697.00 million for the quarter, compared to analysts’ expectations of $703.

22 million. Fortrea had a positive return on equity of 2.00% and a negative net margin of 10.

99%. During the same quarter in the prior year, the business posted $0.19 EPS.

As a group, equities analysts predict that Fortrea Holdings Inc. will post 0.51 earnings per share for the current year.

Fortrea Company Profile ( Free Report ) Fortrea Holdings Inc, a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum.

See Also Five stocks we like better than Fortrea 10 Best Airline Stocks to Buy How to Invest in Micro-Cap Stocks Like a Pro What is Insider Trading? What You Can Learn from Insider Trading Investors Sell Microsoft Stock on OpenAI News—Time to Buy? The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number Take-Two Interactive: A Defensive Play Set to Explode Want to see what other hedge funds are holding FTRE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fortrea Holdings Inc. ( NASDAQ:FTRE – Free Report ).

Receive News & Ratings for Fortrea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortrea and related companies with MarketBeat.com's FREE daily email newsletter ..